Article Text

PDF
Letter
Proton pump inhibitors and risk of gastric cancer in a case–control study
  1. Shih-Wei Lai1,2,
  2. Hsueh-Chou Lai3,4,
  3. Cheng-Li Lin1,5,
  4. Kuan-Fu Liao6,7
  1. 1College of Medicine, China Medical University, Taichung, Taiwan
  2. 2Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3College of Chinese Medicine, China Medical University, Taichung, Taiwan
  4. 4Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
  5. 5Management Office for Health Data, China Medical University, Taichung, Taiwan
  6. 6College of Medicine, Tzu Chi University, Hualien, Taiwan
  7. 7Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao, Division of Hepatogastroenterology, Department of Internal Medicine , Taichung Tzu Chi General Hospital, Taichung City, 427, Taiwan; kuanfuliaog{at}gmail.com

Statistics from Altmetric.com

We read four manuscripts published in Gut about the relationship between proton pump inhibitors use and gastric cancer.1–4 Proton pump inhibitors are widely used for the management of peptic ulcer disease,  gastroesophageal reflux disease and eradication of Helicobacter pylori infection.5 However, its safety for long-term use has raised pubic concern.6 In order to clarify the relationship between proton pump inhibitors use and gastric cancer, we used the 2000–2013 database of Taiwan National Health Insurance Program to conduct a population-based case–control study. The study design and data source were adapted from previous studies.7 8 Subjects aged 20–84 years with newly diagnosed gastric cancer were selected as the cases. Subjects without gastric cancer were randomly selected from the same database as the matched controls. The index date was defined as the date of each case being diagnosed with gastric cancer. Both cases with gastric cancer and matched controls were matched with sex, age (every five years) and the year of index date. In order to reduce the latency bias, subjects whose first-time prescriptions for proton pump …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.